Hospital-acquired pneumonia (HAP) or nosocomial pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48–72 hours after being admitted. It is thus distinguished from community-acquired pneumonia. It is usually caused by a bacterial infection, rather than a virus.
Market Analysis and Insights: Global Hospital Acquired Pneumonia Drugs Market
Prior to COVID-19, the market for Hospital Acquired Pneumonia Drugs was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of XX% during 2021–2026, whereas post-COVID-19 scenario, the market for Hospital Acquired Pneumonia Drugs is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Hospital Acquired Pneumonia Drugs market.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Hospital Acquired Pneumonia Drugs market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Hospital Acquired Pneumonia Drugs industry.
Global Hospital Acquired Pneumonia Drugs Scope and Segment
Hospital Acquired Pneumonia Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hospital Acquired Pneumonia Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.
The following manufacturers are covered in this report:
Basilea Pharmaceutica
Meiji Holdings
Cubist Pharmaceutical
Aridis Pharmaceutical
Valneva
Bayer
GlaxoSmithKline
Merck
Achaogen
AstraZeneca
Hospital Acquired Pneumonia Drugs Breakdown Data by Type
Phase II
Early Phase (Phase I & II)
Hospital Acquired Pneumonia Drugs Breakdown Data by Application
Hospital Pharmacies
Retail Pharmacies
Drug Store
E-Commerce
Regional and Country-level Analysis
The Hospital Acquired Pneumonia Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Hospital Acquired Pneumonia Drugs market report are North America, Europe, China and Japan. It also covers key regions (countries), viz, the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of production capacity, price and revenue for the period 2015-2026.
Competitive Landscape and Hospital Acquired Pneumonia Drugs Market Share Analysis
Market Analysis and Insights: Global Hospital Acquired Pneumonia Drugs Market
Prior to COVID-19, the market for Hospital Acquired Pneumonia Drugs was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of XX% during 2021–2026, whereas post-COVID-19 scenario, the market for Hospital Acquired Pneumonia Drugs is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Hospital Acquired Pneumonia Drugs market.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Hospital Acquired Pneumonia Drugs market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Hospital Acquired Pneumonia Drugs industry.
Global Hospital Acquired Pneumonia Drugs Scope and Segment
Hospital Acquired Pneumonia Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hospital Acquired Pneumonia Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.
The following manufacturers are covered in this report:
Basilea Pharmaceutica
Meiji Holdings
Cubist Pharmaceutical
Aridis Pharmaceutical
Valneva
Bayer
GlaxoSmithKline
Merck
Achaogen
AstraZeneca
Hospital Acquired Pneumonia Drugs Breakdown Data by Type
Phase II
Early Phase (Phase I & II)
Hospital Acquired Pneumonia Drugs Breakdown Data by Application
Hospital Pharmacies
Retail Pharmacies
Drug Store
E-Commerce
Regional and Country-level Analysis
The Hospital Acquired Pneumonia Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Hospital Acquired Pneumonia Drugs market report are North America, Europe, China and Japan. It also covers key regions (countries), viz, the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of production capacity, price and revenue for the period 2015-2026.
Competitive Landscape and Hospital Acquired Pneumonia Drugs Market Share Analysis
1 Study Coverage
1.1 Hospital Acquired Pneumonia Drugs Product Introduction
1.2 Market Segments
1.3 Key Hospital Acquired Pneumonia Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Hospital Acquired Pneumonia Drugs Market Size Growth Rate by Type
1.4.2 Phase II
1.4.3 Early Phase (Phase I & II)
1.5 Market by Application
1.5.1 Global Hospital Acquired Pneumonia Drugs Market Size Growth Rate by Application
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Drug Store
1.5.5 E-Commerce
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Hospital Acquired Pneumonia Drugs Market Size, Estimates and Forecasts
2.1.1 Global Hospital Acquired Pneumonia Drugs Revenue 2015-2026
2.1.2 Global Hospital Acquired Pneumonia Drugs Sales 2015-2026
2.2 Global Hospital Acquired Pneumonia Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Hospital Acquired Pneumonia Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Hospital Acquired Pneumonia Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Hospital Acquired Pneumonia Drugs Competitor Landscape by Players
3.1 Hospital Acquired Pneumonia Drugs Sales by Manufacturers
3.1.1 Hospital Acquired Pneumonia Drugs Sales by Manufacturers (2015-2020)
3.1.2 Hospital Acquired Pneumonia Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Hospital Acquired Pneumonia Drugs Revenue by Manufacturers
3.2.1 Hospital Acquired Pneumonia Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Hospital Acquired Pneumonia Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hospital Acquired Pneumonia Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Hospital Acquired Pneumonia Drugs Revenue in 2019
3.2.5 Global Hospital Acquired Pneumonia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Hospital Acquired Pneumonia Drugs Price by Manufacturers
3.4 Hospital Acquired Pneumonia Drugs Manufacturing Base Distribution, Product Types
3.4.1 Hospital Acquired Pneumonia Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hospital Acquired Pneumonia Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Hospital Acquired Pneumonia Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hospital Acquired Pneumonia Drugs Market Size by Type (2015-2020)
4.1.1 Global Hospital Acquired Pneumonia Drugs Sales by Type (2015-2020)
4.1.2 Global Hospital Acquired Pneumonia Drugs Revenue by Type (2015-2020)
4.1.3 Hospital Acquired Pneumonia Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Hospital Acquired Pneumonia Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Hospital Acquired Pneumonia Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Hospital Acquired Pneumonia Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Hospital Acquired Pneumonia Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Hospital Acquired Pneumonia Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Hospital Acquired Pneumonia Drugs Market Size by Application (2015-2020)
5.1.1 Global Hospital Acquired Pneumonia Drugs Sales by Application (2015-2020)
5.1.2 Global Hospital Acquired Pneumonia Drugs Revenue by Application (2015-2020)
5.1.3 Hospital Acquired Pneumonia Drugs Price by Application (2015-2020)
5.2 Hospital Acquired Pneumonia Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Hospital Acquired Pneumonia Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Hospital Acquired Pneumonia Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Hospital Acquired Pneumonia Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Hospital Acquired Pneumonia Drugs by Country
6.1.1 North America Hospital Acquired Pneumonia Drugs Sales by Country
6.1.2 North America Hospital Acquired Pneumonia Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Hospital Acquired Pneumonia Drugs Market Facts & Figures by Type
6.3 North America Hospital Acquired Pneumonia Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Hospital Acquired Pneumonia Drugs by Country
7.1.1 Europe Hospital Acquired Pneumonia Drugs Sales by Country
7.1.2 Europe Hospital Acquired Pneumonia Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hospital Acquired Pneumonia Drugs Market Facts & Figures by Type
7.3 Europe Hospital Acquired Pneumonia Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Hospital Acquired Pneumonia Drugs by Region
8.1.1 Asia Pacific Hospital Acquired Pneumonia Drugs Sales by Region
8.1.2 Asia Pacific Hospital Acquired Pneumonia Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Hospital Acquired Pneumonia Drugs Market Facts & Figures by Type
8.3 Asia Pacific Hospital Acquired Pneumonia Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Hospital Acquired Pneumonia Drugs by Country
9.1.1 Latin America Hospital Acquired Pneumonia Drugs Sales by Country
9.1.2 Latin America Hospital Acquired Pneumonia Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Hospital Acquired Pneumonia Drugs Market Facts & Figures by Type
9.3 Central & South America Hospital Acquired Pneumonia Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Hospital Acquired Pneumonia Drugs by Country
10.1.1 Middle East and Africa Hospital Acquired Pneumonia Drugs Sales by Country
10.1.2 Middle East and Africa Hospital Acquired Pneumonia Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Hospital Acquired Pneumonia Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Hospital Acquired Pneumonia Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Basilea Pharmaceutica
11.1.1 Basilea Pharmaceutica Corporation Information
11.1.2 Basilea Pharmaceutica Description and Business Overview
11.1.3 Basilea Pharmaceutica Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Products Offered
11.1.5 Basilea Pharmaceutica Related Developments
11.2 Meiji Holdings
11.2.1 Meiji Holdings Corporation Information
11.2.2 Meiji Holdings Description and Business Overview
11.2.3 Meiji Holdings Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Meiji Holdings Hospital Acquired Pneumonia Drugs Products Offered
11.2.5 Meiji Holdings Related Developments
11.3 Cubist Pharmaceutical
11.3.1 Cubist Pharmaceutical Corporation Information
11.3.2 Cubist Pharmaceutical Description and Business Overview
11.3.3 Cubist Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Cubist Pharmaceutical Hospital Acquired Pneumonia Drugs Products Offered
11.3.5 Cubist Pharmaceutical Related Developments
11.4 Aridis Pharmaceutical
11.4.1 Aridis Pharmaceutical Corporation Information
11.4.2 Aridis Pharmaceutical Description and Business Overview
11.4.3 Aridis Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Aridis Pharmaceutical Hospital Acquired Pneumonia Drugs Products Offered
11.4.5 Aridis Pharmaceutical Related Developments
11.5 Valneva
11.5.1 Valneva Corporation Information
11.5.2 Valneva Description and Business Overview
11.5.3 Valneva Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Valneva Hospital Acquired Pneumonia Drugs Products Offered
11.5.5 Valneva Related Developments
11.6 Bayer
11.6.1 Bayer Corporation Information
11.6.2 Bayer Description and Business Overview
11.6.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Bayer Hospital Acquired Pneumonia Drugs Products Offered
11.6.5 Bayer Related Developments
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Corporation Information
11.7.2 GlaxoSmithKline Description and Business Overview
11.7.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.7.4 GlaxoSmithKline Hospital Acquired Pneumonia Drugs Products Offered
11.7.5 GlaxoSmithKline Related Developments
11.8 Merck
11.8.1 Merck Corporation Information
11.8.2 Merck Description and Business Overview
11.8.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Merck Hospital Acquired Pneumonia Drugs Products Offered
11.8.5 Merck Related Developments
11.9 Achaogen
11.9.1 Achaogen Corporation Information
11.9.2 Achaogen Description and Business Overview
11.9.3 Achaogen Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Achaogen Hospital Acquired Pneumonia Drugs Products Offered
11.9.5 Achaogen Related Developments
11.10 AstraZeneca
11.10.1 AstraZeneca Corporation Information
11.10.2 AstraZeneca Description and Business Overview
11.10.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.10.4 AstraZeneca Hospital Acquired Pneumonia Drugs Products Offered
11.10.5 AstraZeneca Related Developments
11.1 Basilea Pharmaceutica
11.1.1 Basilea Pharmaceutica Corporation Information
11.1.2 Basilea Pharmaceutica Description and Business Overview
11.1.3 Basilea Pharmaceutica Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Products Offered
11.1.5 Basilea Pharmaceutica Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Hospital Acquired Pneumonia Drugs Market Estimates and Projections by Region
12.1.1 Global Hospital Acquired Pneumonia Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Hospital Acquired Pneumonia Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Hospital Acquired Pneumonia Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Hospital Acquired Pneumonia Drugs Sales Forecast (2021-2026)
12.2.2 North America: Hospital Acquired Pneumonia Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Hospital Acquired Pneumonia Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Hospital Acquired Pneumonia Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Hospital Acquired Pneumonia Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Hospital Acquired Pneumonia Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Hospital Acquired Pneumonia Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Hospital Acquired Pneumonia Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Hospital Acquired Pneumonia Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Hospital Acquired Pneumonia Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Hospital Acquired Pneumonia Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Hospital Acquired Pneumonia Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Hospital Acquired Pneumonia Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Hospital Acquired Pneumonia Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Hospital Acquired Pneumonia Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Hospital Acquired Pneumonia Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Hospital Acquired Pneumonia Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Hospital Acquired Pneumonia Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Hospital Acquired Pneumonia Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Hospital Acquired Pneumonia Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hospital Acquired Pneumonia Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
1.1 Hospital Acquired Pneumonia Drugs Product Introduction
1.2 Market Segments
1.3 Key Hospital Acquired Pneumonia Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Hospital Acquired Pneumonia Drugs Market Size Growth Rate by Type
1.4.2 Phase II
1.4.3 Early Phase (Phase I & II)
1.5 Market by Application
1.5.1 Global Hospital Acquired Pneumonia Drugs Market Size Growth Rate by Application
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Drug Store
1.5.5 E-Commerce
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Hospital Acquired Pneumonia Drugs Market Size, Estimates and Forecasts
2.1.1 Global Hospital Acquired Pneumonia Drugs Revenue 2015-2026
2.1.2 Global Hospital Acquired Pneumonia Drugs Sales 2015-2026
2.2 Global Hospital Acquired Pneumonia Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Hospital Acquired Pneumonia Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Hospital Acquired Pneumonia Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Hospital Acquired Pneumonia Drugs Competitor Landscape by Players
3.1 Hospital Acquired Pneumonia Drugs Sales by Manufacturers
3.1.1 Hospital Acquired Pneumonia Drugs Sales by Manufacturers (2015-2020)
3.1.2 Hospital Acquired Pneumonia Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Hospital Acquired Pneumonia Drugs Revenue by Manufacturers
3.2.1 Hospital Acquired Pneumonia Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Hospital Acquired Pneumonia Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hospital Acquired Pneumonia Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Hospital Acquired Pneumonia Drugs Revenue in 2019
3.2.5 Global Hospital Acquired Pneumonia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Hospital Acquired Pneumonia Drugs Price by Manufacturers
3.4 Hospital Acquired Pneumonia Drugs Manufacturing Base Distribution, Product Types
3.4.1 Hospital Acquired Pneumonia Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hospital Acquired Pneumonia Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Hospital Acquired Pneumonia Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hospital Acquired Pneumonia Drugs Market Size by Type (2015-2020)
4.1.1 Global Hospital Acquired Pneumonia Drugs Sales by Type (2015-2020)
4.1.2 Global Hospital Acquired Pneumonia Drugs Revenue by Type (2015-2020)
4.1.3 Hospital Acquired Pneumonia Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Hospital Acquired Pneumonia Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Hospital Acquired Pneumonia Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Hospital Acquired Pneumonia Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Hospital Acquired Pneumonia Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Hospital Acquired Pneumonia Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Hospital Acquired Pneumonia Drugs Market Size by Application (2015-2020)
5.1.1 Global Hospital Acquired Pneumonia Drugs Sales by Application (2015-2020)
5.1.2 Global Hospital Acquired Pneumonia Drugs Revenue by Application (2015-2020)
5.1.3 Hospital Acquired Pneumonia Drugs Price by Application (2015-2020)
5.2 Hospital Acquired Pneumonia Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Hospital Acquired Pneumonia Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Hospital Acquired Pneumonia Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Hospital Acquired Pneumonia Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Hospital Acquired Pneumonia Drugs by Country
6.1.1 North America Hospital Acquired Pneumonia Drugs Sales by Country
6.1.2 North America Hospital Acquired Pneumonia Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Hospital Acquired Pneumonia Drugs Market Facts & Figures by Type
6.3 North America Hospital Acquired Pneumonia Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Hospital Acquired Pneumonia Drugs by Country
7.1.1 Europe Hospital Acquired Pneumonia Drugs Sales by Country
7.1.2 Europe Hospital Acquired Pneumonia Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hospital Acquired Pneumonia Drugs Market Facts & Figures by Type
7.3 Europe Hospital Acquired Pneumonia Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Hospital Acquired Pneumonia Drugs by Region
8.1.1 Asia Pacific Hospital Acquired Pneumonia Drugs Sales by Region
8.1.2 Asia Pacific Hospital Acquired Pneumonia Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Hospital Acquired Pneumonia Drugs Market Facts & Figures by Type
8.3 Asia Pacific Hospital Acquired Pneumonia Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Hospital Acquired Pneumonia Drugs by Country
9.1.1 Latin America Hospital Acquired Pneumonia Drugs Sales by Country
9.1.2 Latin America Hospital Acquired Pneumonia Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Hospital Acquired Pneumonia Drugs Market Facts & Figures by Type
9.3 Central & South America Hospital Acquired Pneumonia Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Hospital Acquired Pneumonia Drugs by Country
10.1.1 Middle East and Africa Hospital Acquired Pneumonia Drugs Sales by Country
10.1.2 Middle East and Africa Hospital Acquired Pneumonia Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Hospital Acquired Pneumonia Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Hospital Acquired Pneumonia Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Basilea Pharmaceutica
11.1.1 Basilea Pharmaceutica Corporation Information
11.1.2 Basilea Pharmaceutica Description and Business Overview
11.1.3 Basilea Pharmaceutica Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Products Offered
11.1.5 Basilea Pharmaceutica Related Developments
11.2 Meiji Holdings
11.2.1 Meiji Holdings Corporation Information
11.2.2 Meiji Holdings Description and Business Overview
11.2.3 Meiji Holdings Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Meiji Holdings Hospital Acquired Pneumonia Drugs Products Offered
11.2.5 Meiji Holdings Related Developments
11.3 Cubist Pharmaceutical
11.3.1 Cubist Pharmaceutical Corporation Information
11.3.2 Cubist Pharmaceutical Description and Business Overview
11.3.3 Cubist Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Cubist Pharmaceutical Hospital Acquired Pneumonia Drugs Products Offered
11.3.5 Cubist Pharmaceutical Related Developments
11.4 Aridis Pharmaceutical
11.4.1 Aridis Pharmaceutical Corporation Information
11.4.2 Aridis Pharmaceutical Description and Business Overview
11.4.3 Aridis Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Aridis Pharmaceutical Hospital Acquired Pneumonia Drugs Products Offered
11.4.5 Aridis Pharmaceutical Related Developments
11.5 Valneva
11.5.1 Valneva Corporation Information
11.5.2 Valneva Description and Business Overview
11.5.3 Valneva Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Valneva Hospital Acquired Pneumonia Drugs Products Offered
11.5.5 Valneva Related Developments
11.6 Bayer
11.6.1 Bayer Corporation Information
11.6.2 Bayer Description and Business Overview
11.6.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Bayer Hospital Acquired Pneumonia Drugs Products Offered
11.6.5 Bayer Related Developments
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Corporation Information
11.7.2 GlaxoSmithKline Description and Business Overview
11.7.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.7.4 GlaxoSmithKline Hospital Acquired Pneumonia Drugs Products Offered
11.7.5 GlaxoSmithKline Related Developments
11.8 Merck
11.8.1 Merck Corporation Information
11.8.2 Merck Description and Business Overview
11.8.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Merck Hospital Acquired Pneumonia Drugs Products Offered
11.8.5 Merck Related Developments
11.9 Achaogen
11.9.1 Achaogen Corporation Information
11.9.2 Achaogen Description and Business Overview
11.9.3 Achaogen Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Achaogen Hospital Acquired Pneumonia Drugs Products Offered
11.9.5 Achaogen Related Developments
11.10 AstraZeneca
11.10.1 AstraZeneca Corporation Information
11.10.2 AstraZeneca Description and Business Overview
11.10.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.10.4 AstraZeneca Hospital Acquired Pneumonia Drugs Products Offered
11.10.5 AstraZeneca Related Developments
11.1 Basilea Pharmaceutica
11.1.1 Basilea Pharmaceutica Corporation Information
11.1.2 Basilea Pharmaceutica Description and Business Overview
11.1.3 Basilea Pharmaceutica Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Products Offered
11.1.5 Basilea Pharmaceutica Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Hospital Acquired Pneumonia Drugs Market Estimates and Projections by Region
12.1.1 Global Hospital Acquired Pneumonia Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Hospital Acquired Pneumonia Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Hospital Acquired Pneumonia Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Hospital Acquired Pneumonia Drugs Sales Forecast (2021-2026)
12.2.2 North America: Hospital Acquired Pneumonia Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Hospital Acquired Pneumonia Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Hospital Acquired Pneumonia Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Hospital Acquired Pneumonia Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Hospital Acquired Pneumonia Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Hospital Acquired Pneumonia Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Hospital Acquired Pneumonia Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Hospital Acquired Pneumonia Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Hospital Acquired Pneumonia Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Hospital Acquired Pneumonia Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Hospital Acquired Pneumonia Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Hospital Acquired Pneumonia Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Hospital Acquired Pneumonia Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Hospital Acquired Pneumonia Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Hospital Acquired Pneumonia Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Hospital Acquired Pneumonia Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Hospital Acquired Pneumonia Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Hospital Acquired Pneumonia Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Hospital Acquired Pneumonia Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hospital Acquired Pneumonia Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
